The World Health Organisation (WHO) and the International Agency for the Prevention of Blindness has made childhood blindness a significant priority for their VISION 2020 joint global initiative. Retinopathy of prematurity (ROP) is an eye condition that strikes premature babies.
The disorder can result in visual impairment and irreversible blindness. In an effort to address childhood blindness, Bayer is testing its blockbuster aflibercept eye drug, Eylea, to prevent blindness in premature infants. Eylea is approved to treat wet age-related macular degeneration (AMD), diabetic retinopathy, and diabetic macular edema.
San Diego Center for the Blind offers programs to help people struggling with vision impairment and blindness. Please contact us to learn more.
“Bayer begins phase 3 trial testing aflibercept in infant blindness”